Firefly Neuroscience (NASDAQ:AIFF) Shares Down 1.8% – Here’s Why

Firefly Neuroscience, Inc. (NASDAQ:AIFF)’s share price dropped 1.8% on Friday . The stock traded as low as $1.09 and last traded at $1.10. Approximately 83,270 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 206,779 shares. The stock had previously closed at $1.12.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Firefly Neuroscience Stock Down 1.8%

The business’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $2.29. The company has a market cap of $14.84 million, a price-to-earnings ratio of -0.53 and a beta of 1.85.

Firefly Neuroscience (NASDAQ:AIFF) last announced its earnings results on Wednesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $0.39 million during the quarter. Firefly Neuroscience had a negative net margin of 2,705.88% and a negative return on equity of 319.00%.

Insider Activity

In other news, major shareholder Windsor Private Capital Lp sold 78,031 shares of Firefly Neuroscience stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $2.07, for a total value of $161,524.17. Following the sale, the insider owned 1,236,773 shares of the company’s stock, valued at $2,560,120.11. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 295,064 shares of company stock valued at $725,218 over the last quarter. Insiders own 6.44% of the company’s stock.

Institutional Trading of Firefly Neuroscience

Institutional investors have recently added to or reduced their stakes in the stock. Savvy Advisors Inc. purchased a new position in Firefly Neuroscience in the 3rd quarter valued at about $63,000. Geode Capital Management LLC raised its position in shares of Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after buying an additional 401,085 shares during the period. Hedge funds and other institutional investors own 4.96% of the company’s stock.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.